46,630 - 46,630
FENTORA 29,250 - 29,250
AMRIX - - -
Pain 176,762 8,039 184,801
Other 14,423 55,841 70,264
$394,828 $78,519 $473,347
%
Increase
(Decrease)
United
States Europe Total
Sales:
PROVIGIL 9% (19%) 7%
GABITRIL (15%) (50%) (18%)
CNS 8% (21%) 6%
ACTIQ (58%) 50% (50%)
Generic OTFC (33%) 0% (33%)
FENTORA 16% 0% 16%
AMRIX 100% 0% 100%
Pain (34%) 50% (31%)
Other 7% 17% 15%
(11%) 13% (7%)
Year Ended
December 31,
2007
United
States Europe Total
Sales:
PROVIGIL $801,639 $50,408 $852,047
GABITRIL 50,642 6,668 57,310
CNS 852,281 57,076 909,357
ACTIQ
'/>"/>
SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related biology technology :1.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results2.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain3.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results4.
CNS Response Announces Fiscal Third Quarter 2007 Results5.
Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results6.
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results7.
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20078.
Carrington Reports Second Quarter 2007 Results9.
Avitar Reports Third Quarter Financial Results for Fiscal 200710.
Response Genetics Reports Second Quarter 2007 Financial Results11.
Martek to Announce Third Quarter 2007 Results on September 5, 2007